H.R. 5467
119th CONGRESS 1st Session
To amend title XVIII of the Social Security Act to require coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D.
IN THE HOUSE OF REPRESENTATIVES · September 18, 2025 · Sponsor: Ms. Johnson of Texas
Table of contents
SEC. 1. Short title
- This Act may be cited as the or the .
SEC. 2. Requiring coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D
- Section 1860D–4 of the Social Security Act () is amended— 42 U.S.C. 1395w–104
- (J) Required inclusion of certain drugs for autoimmune diseases and blood disorders
- (i) For 2027 and each subsequent year, a PDP sponsor offering a prescription drug plan shall include each covered part D drug that is an autoimmune or blood disorder drug described in .
- (ii) For purposes of , a drug described in this clause is a covered part D drug indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease.
- in subsection (b)(3), by adding at the end the following new subparagraph:
- in subsection (c)—
- by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (), as paragraph (7); and Public Law 115–123
- (8) Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs
- For plan years beginning on or after January 1, 2027, a PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) may not require, with respect to an individual enrolled under such plan, that prior authorization for an autoimmune or blood disorder drug (as described in subsection (b)(3)(J)(ii)) be obtained more than once during any 12-month period unless such drug is—
- typically used for a period of 12 months or less;
- an opioid, a benzodiazepine, a barbiturate, or carisoprodol; or
- a drug with respect to which a risk evaluation and mitigation strategy is required under Section 505–1 of the Federal Food, Drug, and Cosmetic Act.
- For plan years beginning on or after January 1, 2027, a PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) may not require, with respect to an individual enrolled under such plan, that prior authorization for an autoimmune or blood disorder drug (as described in subsection (b)(3)(J)(ii)) be obtained more than once during any 12-month period unless such drug is—
- (8) Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs
- by adding at the end the following new paragraph:
- by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (), as paragraph (7); and Public Law 115–123
- (J) Required inclusion of certain drugs for autoimmune diseases and blood disorders